Charles Ornstein & Katie Thomas
Charles Ornstein is a senior reporter for ProPublica covering health care and the pharmaceutical industry.
Generic Drug Prices Are Dropping, but Who Is This Really Benefiting?
It seems that overall drug spending is still on the rise because of the skyrocketing price of new, brand-name drugs.
Corporate Incentives Make Insurers Favor Pushing Brand-Name Drugs Over Cheaper Generics
Out of public view, corporations are cutting deals that give consumers little choice but to buy brand-name drugs—and sometimes pay more at the pharmacy counter than they would for generics.
Behind Pharmaceutical Companies' Money-Back Guarantees
Drugmakers are increasingly agreeing to refund money if patients don't respond to medications as expected.